|
|
發表於 2011-11-13 21:37:32
|
顯示全部樓層
本帖最後由 蘇少儀 於 2011-11-14 02:12 編輯
阿燦可以拿這個歐盟正式網頁內容給公司
向總公司轉達，別拿台灣做試驗...............................
台灣的產官學研也可以做一下參考．
別人已經說不行的路就別往裡面走.......................
CSFV_goDIVA
Project Background
The economic and socio-economic impact of CSF is very high worldwide, including the territories of the EU. In 1993 and 1994, 10.7 and 21.4 million Euros respectively were spent on outbreaks in Belgium and Germany, with a further 130 million Euros of market support in 1994. In 1997, an epizootic outbreak centred in The Netherlands resulted in the compulsory slaughter and disposal of more than 10 million pigs, with costs estimated at over one billion Euros. An estimation of the overall economic loss results in several times these amounts. However, the situation is dynamic and also very recently (2006) more than 120000 pigs had to be culled in Germany due to a small outbreak of CSFV in domestic pigs.
Eradication of CSF in domestic pigs has been achieved in several areas within the EU. However, despite intensive efforts on national as well as on international level, the complete eradication of CSF in Europe has proved to be elusive. Additionally, the disease is still endemic in some new EU member states (Romania and Bulgaria) and sporadic outbreaks still occur in free areas. The latter is most likely due to the persistence of the virus in wild boar populations, which acts as a reservoir for the virus. Furthermore, population dynamics in back yard pigs is not fully understood, as this type of pig holdings is new to the European Community and hasn't been fully investigated. As a consequence, there is a strong need for improvement of knowledge and intervention strategies for back yard pigs.
Currently a non-vaccination policy exists in the EU. However, due to the problems in wild boar and in domestic pigs in some member states derogations of this non-vaccination policy and some field trials are ongoing. In case of oral vaccinations in wild boar, the live C-strain vaccine is used, since only live vaccines can be used for oral vaccination. The disadvantage of this vaccine is that no differentiation between vaccinated and infected animals can be made. In Romania and Bulgaria some herds are vaccinated with the registered marker vaccine based on a baculovirus produced E2 subunit vaccine. As this use of the E2 marker vaccine is new, some very valuable information on the field use of this vaccine could be made available from these countries. Nevertheless, some experimental studies demonstrated that the licensed E2-subunit marker vaccines are not efficacious enough for use as emergency vaccines in domestic pigs, and in addition can not be used in bait vaccines for oral immunization of wild boar. Controlling CSFV outbreaks in domestic pigs as well as in wild boar and back yard herds would be significantly enhanced, if a safe and efficient live marker vaccine would be available with its accompanying DIVA assays. |
|
IP卡
狗仔卡
顯身卡
[信息未更新]
